Summit Therapeutics (SMMT) Free Cash Flow (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Free Cash Flow data on file, last reported at -$141.3 million in Q2 2026.

• Quarterly Free Cash Flow fell 104.85% year-over-year to -$141.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$456.7 million (down 114.26% YoY) and the FY2025 annual result came in at -$323.6 million, down 127.49% from the prior year.
• Free Cash Flow eased to -$141.3 million in Q2 2026, from -$123.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $5.2 million in Q4 2022 to a low of -$141.3 million in Q2 2026.
• A 5-year average of -$47.2 million and a median of -$29.8 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 155.93% — and 2023, when it slumped 474.18%.
• Tracing SMMT's Free Cash Flow over 5 years: stood at $5.2 million in 2022, then tumbled by 474.18% to -$19.5 million in 2023, then slumped by 163.44% to -$51.3 million in 2024, then plunged by 91.28% to -$98.1 million in 2025, then slumped by 44.13% to -$141.3 million in 2026.
• The last three Free Cash Flow figures came in at -$141.3 million (Q2 2026), -$123.3 million (Q1 2026), and -$98.1 million (Q4 2025), per Business Quant data.